Virginia Tech® home

Evaluating a Clotting Enzyme in Dogs with Protein Losing Nephropathy

Plasma ADAMTS13 activity in dogs with protein losing nephropathy

Principal Investigator

Contacts

Robyn Fox, LVT
Clinical Trials Coordinator

Purpose

The purpose of this study is to evaluate a clotting enzyme, ADAMTS13, in dogs with protein losing nephropathy (PLN) compared to healthy dogs.

Background

Protein losing nephropathy is a kidney disease that causes protein loss in urine and a high risk of blood clots in dogs. Because humans with kidney disease show a deficiency in the clot-preventing enzyme ADAMTS13, studying this enzyme in dogs may explain why these clots occur. This information could eventually lead to better diagnostic tools and targeted treatments for canine patients.

Eligibility

  1. Dogs diagnosed with Protein Losing Nepropathy based on bloodwork and urinalysis
  2. Dogs must have a UPC of ≥ 2 with no evidence of pre- or post-renal proteinuria

Exclusion Criteria

  • Dogs with major concurrent disease unrelated to their PLN

Study Design

Dogs presenting with PLN that meet the criteria will receive a renal panel, urinalysis with urine protein to creatinine ratio (UPC).  Extra blood will be drawn to evaluate ADAMTS13.  Results from the renal panel, urinalysis and UPC will be shared with the pet's attending clinician.

Compensation

The cost of the research exam, renal blood panel, urinalysis with UPC, and study-specific sample will be covered by the study.

Funded by

  • Article Item
    Cat and dog resting together
    Veterinary Memorial Fund-Funded Research , article

    Since its founding, the Veterinary Memorial Fund has supported more than 100 different projects to foster improved veterinary medical care. The fund has helped scientists develop knowledge, improve procedures, and perfect techniques in such areas as genetics, imaging technologies, chemotherapy, wound healing, dental disease, and equine laminitis.